Investors & Media

press releases

There are currently no events to display.
Date Title Teaser
12/03/18
Summary Togglebluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology LentiGlobin treatment-derived hemoglobin HbA T87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment Total hemoglobin levels stable after month three and reach range of 9.9 – 13.7 g/dL in patients who are at least six months post treatment No reports
12/03/18
Summary Togglebluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology First presentation of data from patients with a β 0 /β 0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have stopped chronic blood transfusions 10 of 11 patients with non-β 0 /β 0 genotypes and more than three months follow-up have stopped chronic
12/02/18
Summary Togglebluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting bb21217 early safety profile consistent with CAR T platform therapies 83 percent objective response rate in 12 heavily pretreated multiple myeloma patients at first dose level studied Higher dose of bb21217 being assessed in the ongoing Phase 1 study CAMBRIDGE, Mass. & SUMMIT, N.J.
12/01/18
Summary Togglebluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology All patients with transfusion-dependent β-thalassemia and a non-β 0 /β 0 genotype who achieved transfusion independence continue to maintain it for up to 3.5 years in Phase 1/2 Northstar (HGB-204) study HbA T87Q levels were stable and vaso-occlusive events were reduced in most Group A and B
11/30/18
Summary Togglebluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 30, 2018-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the company will host a live webcast of an investor and analyst event being held on Monday, December 3, 2018 , during the 60 th Annual Meeting of the American Society of Hematology (ASH).
11/27/18
Summary ToggleCelgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma SUMMIT, N.J. & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients
11/15/18
Summary Togglebluebird bio to Present at the Evercore ISI HealthCONx Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference , Wednesday, November 28 , at 4:15 p.m. ET at the Boston Harbor Hotel , Boston .
11/01/18
Summary Togglebluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress – Company plans to pursue accelerated development pathway for LentiGlobin TM in sickle cell disease (SCD) – – Ended quarter with $2.0 billion in cash, cash equivalents and marketable securities – – Company to hold conference call and webcast to discuss ASH abstracts and development plans for SCD
11/01/18
Summary Togglebluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting – Initial data from Phase 3 studies of LentiGlobin™ gene therapy in transfusion-dependent β-thalassemia for β 0 /β 0 genotype and updated data in non-β 0 /β 0 genotype – – Updated data from Phase 1 study of LentiGlobin in sickle cell disease – – Initial efficacy and safety results from Phase 1
10/05/18
Summary Togglebluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia - European Medicines Agency Will Evaluate LentiGlobin Marketing Authorization Application Under Accelerated Assessment - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2018-- bluebird bio, Inc . (Nasdaq: BLUE) announced today that the European Medicines Agency (EMA) accepted the company’s marketing
10/01/18
Summary Togglebluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3 , at 3:30 p.m.
09/05/18
Summary Togglebluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoietic Stem Cell Transplant in CALD at 2018 SSIEM − Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results – − General Agreement Reached on Regulatory Pathway for Lenti-D in the U.S. and EU – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- bluebird bio, Inc .
08/29/18
Summary Togglebluebird bio to Present at Investor Conferences in September

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Citi 13 th Annual Biotech Conference , Wednesday, September 5 , 10:30 a.m.

08/23/18
Summary Togglebluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies

CAMBRIDGE, Mass. & EMERYVILLE, Calif. --(BUSINESS WIRE)--Aug. 23, 2018-- bluebird bio , Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

08/06/18
Summary Togglebluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer

CAMBRIDGE, Mass. & TARRYTOWN, N.Y. --(BUSINESS WIRE)--Aug. 6, 2018-- bluebird bio, Inc. (NASDAQ: BLUE ) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel

08/03/18
Summary Togglebluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium

− Data Include Updates from Phase 2/3 Starbeam (ALD-102) Study of Lenti-D for Cerebral Adrenoleukodystrophy (CALD) and Initial Data from Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug.

08/03/18
Summary Togglebluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference , Tuesday, August 14 , at 8:35 a.m. ET at the Parker New York Hotel , New York City .

08/02/18
Summary Togglebluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress

- Lenti-D™ granted Priority Medicines (PRIME) designation from European Medicines Agency (EMA) and Breakthrough Designation from U.S. Food and Drug Administration ( FDA ) in cerebral adrenoleukodystrophy (CALD) – - LentiGlobin™ in transfusion-dependent β-thalassemia (TDT) granted accelerated

07/27/18
Summary Togglebluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 27, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full

07/26/18
Summary Togglebluebird bio’s LentiGlobin™ Gene Therapy Granted Accelerated Assessment by European Medicines Agency for the Treatment of Transfusion-Dependent β-Thalassemia

− Company on Track to Submit Marketing Authorization Application (MAA) in European Union in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult

07/24/18
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share, before underwriting discounts.

07/23/18
Summary Togglebluebird bio Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional

06/15/18
Summary Togglebluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

– All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbA T87Q – – First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbA T87Q at 6 months – – Company to hold conference call and webcast today, June 15 ,

06/15/18
Summary Togglebluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association

– 7/8 non-β 0 /β 0 patients with ≥ 6 months follow-up producing normal or near-normal amounts of total hemoglobin (11.1 – 13.3 g/dL) and are transfusion free in Northstar-2 Study – – 8/10 of non-β 0 /β 0 patients achieving and maintaining transfusion independence for up to 3 years in Northstar

06/05/18
Summary Togglebluebird bio Announces Investor Events in June

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference , Thursday, June 7 , at 10:00 a.m.

06/01/18
Summary ToggleUpdated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated patients in the active doses of the dose escalation cohort Consistent response observed for both low and high BCMA expression levels
05/23/18
Summary ToggleFDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious

05/17/18
Summary Togglebluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association

- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – - Oral presentation of interim data from patients treated with updated study protocol of Phase 1 HGB-206 study of

05/16/18
Summary Togglebluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

– Presentation will include safety and efficacy data from 21 patients treated in dose-escalation phase and early data from patients treated in dose-expansion phase – – Additional poster exploring the significance of MRD negativity in patients in this study to be presented – – Company to host

05/08/18
Summary Togglebluebird bio to Present at Investor Conferences in May

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank’s 43 rd Annual Health Care Conference , Wednesday, May 9 , at 10:00 a.m.

05/02/18
Summary Togglebluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress

– Completed Northstar study of LentiGlobin in transfusion dependent β-thalassemia (TDT) – – Entered into co-development and co-promotion agreement for bb2121 with Celgene – – Ended quarter with $1.57 billion in cash, cash equivalents and marketable securities – CAMBRIDGE, Mass.

04/18/18
Summary Togglebluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

– Majority (12/13) of patients with non-β 0 /β 0 genotypes were transfusion-free at median 27 months following LentiGlobin treatment – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine

04/16/18
Summary Togglebluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2018-- bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will present at Alliance for Regenerative Medicine’s 6 th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17 , at 11:25 a.m.

03/28/18
Summary Togglebluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

- bluebird and Celgene will share 50% of U.S. costs and profits - - bluebird to receive milestones and royalties on ex-U.S. sales - CAMBRIDGE, Mass. & SUMMIT, N.J. --(BUSINESS WIRE)--Mar. 28, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the

03/07/18
Summary Togglebluebird bio to Present at Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
02/21/18
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress – Company expanding organization and capabilities to prepare three programs for regulatory filing in the next two years – – LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to
02/14/18
Summary Togglebluebird bio Appoints Alison Finger as Chief Commercial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief
02/02/18
Summary Togglebluebird bio to Present at LEERINK Partners Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
01/08/18
Summary Togglebluebird bio Announces Closing of Over-Allotment Option in Public Offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contacts

Jenn Snyder

VP, Corporate Communications

(617) 448-0281

JSnyder@bluebirdbio.com

 

Catherine Falcetti

Senior Director, Corporate Communications

(339) 499-9436

CFalcetti@bluebirdbio.com

 

Investor Contact

Elizabeth Pingpank

Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com